Please provide your email address to receive an email when new articles are posted on . Semaglutide further reduced risk for stroke vs. empagliflozin as treatment for diabetes. Dulaglutide’s impact on ...

NEW ORLEANS — The potential mechanisms by which the sodium-glucose cotransporter-2 (SGLT-2) inhibitor empagliflozin (Jardiance, Lilly/Boehringer Ingelheim) may have reduced cardiovascular death in the ...

A new study, published in JAMA Neurology, finds that people with type 2 diabetes who take two common anti-diabetes medications had a reduced risk of Alzheimer’s and associated dementias. Specifically, ...

Comparative effectiveness study followed adults with type 2 diabetes who initiated SGLT-2 inhibitors from 2014 to 2020. Real-world outcomes largely point to comparable risks of hospitalization for ...

Empagliflozin improved clinical outcomes in patients with acute heart failure (AHF), regardless of blood pressure (BP) levels, with particularly strong benefits observed in those with diastolic BP ...

Phase 2 trial findings support empagliflozin use in patients without diabetes for calcium and uric acid stone prevention. Empagliflozin use can reduce the risk of calcium and uric acid kidney stones ...

Atrial fibrillation (AF) is being increasingly understood not as an isolated electrophysiologic disorder, but as a clinical surface expression of a systemic, comorbidity-driven atrial cardiomyopathy.

Some health-obsessed Americans believe the next antiaging therapeutic already exists—in the medicine cabinets of millions of diabetes patients. The widely used class of drugs, called SGLT2 inhibitors ...

In keeping with current guidelines, either empagliflozin or dapagliflozin can be used for preventing AKI and CKD in patients with type 2 diabetes. Empagliflozin and dapagliflozin are equally effective ...